Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: Data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers.
Level 2 - randomized trial
Pooled post-hoc analysis of three double-blind randomized trials combined with a nationwide registry cohort
PubMed 35229024 · doi:10.1002/trc2.12268
What was done
Researchers evaluated the relationship between glucagon-like peptide-1 (GLP-1) receptor agonist treatment and subsequent dementia diagnosis among patients with type 2 diabetes. The analysis evaluated two sources: pooled data from three randomized, double-blind, placebo-controlled cardiovascular outcome trials (15,820 patients) and a nationwide Danish health and prescription registry cohort (120,054 patients) with long-term follow-up.
What was found
Patients randomized to GLP-1 receptor agonists had a lower rate of dementia compared to placebo (hazard ratio [HR]: 0.47, 95% CI: 0.25–0.86). In the nationwide registry cohort, each additional year of GLP-1 receptor agonist exposure was associated with a lower rate of dementia (HR: 0.89, 95% CI: 0.86–0.93).
Why it matters
This study provides evidence from both clinical trial data and a nationwide population cohort that GLP-1 receptor agonists may reduce the risk of dementia in people with type 2 diabetes, supporting their potential repurposing for Alzheimer's disease.
Limits
Dementia was an exploratory or post-hoc outcome rather than the primary endpoint in the cardiovascular outcome trials. The abstract omits absolute event counts, exact follow-up durations, specific GLP-1 receptor agonist agents used, and potential confounding adjustments in the observational cohort.
Cited by
- supports People taking weight loss drugs like GLP-1 agonists show protection against dementia.